Androgen receptor and growth factor signaling cross-talk in prostate cancer cells

Endocrine-Related Cancer

Volumn 15, Issue 4, 2008, Pages 841-849

  Zhu, Meng Lei ^a   Kyprianou, Natasha ^a  

^a UNIVERSITY OF KENTUCKY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN RECEPTOR; EPIDERMAL GROWTH FACTOR; FIBROBLAST GROWTH FACTOR; GROWTH FACTOR; SOMATOMEDIN C; TRANSFORMING GROWTH FACTOR BETA; VASCULOTROPIN;

CANCER CELL; CANCER GROWTH; CARCINOGENESIS; CELL DEATH; CELL SURVIVAL; DRUG TARGETING; HORMONE ACTION; HUMAN; MOLECULAR INTERACTION; NONHUMAN; PROSTATE CANCER; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; REVIEW; SIGNAL TRANSDUCTION; STROMA;

ANIMALS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MALE; PROSTATIC NEOPLASMS; RECEPTOR CROSS-TALK; RECEPTORS, ANDROGEN; SIGNAL TRANSDUCTION;

EID: 58249122148     PISSN: 13510088     EISSN: None     Source Type: Journal    
DOI: 10.1677/ERC-08-0084     Document Type: Review

References (98)

1. Aaronson DS, Muller M, Neves SR, Chung WC, Jayaram G, Iyengar R & Ram PT 2007 An androgen-IL-6-Stat3 autocrine loop re-routes EGF signal in prostate cancer cells. Molecular and Cellular Endocrinology 270 50-56.
2. Abdulgham J, Gu L, Dagvadorj A, Lutz J, Leiby B, Bonuccelli G, Lisanti MP, Zellweger T, Alanen K, Mirtti T et al. 2008 Stat3 promotes metastatic progression of prostate cancer. American Journal of Pathology 172 1717-1728.
3. Abreu-Martin MT, Chari A, Palladino AA, Craft NA & Sawyers CL 1999 Mitogen-activated protein kinase kinase kinase 1 activates androgen receptor-dependent transcription and apoptosis in prostate cancer. Molecular and Cellular Biology 19 5143-5154.
4. Akhurst RJ & Derynck R 2001 TGF-beta signaling in cancer - a double-edged sword. Trends in Cell Biology 11 S44-S51.
5. Anastasiadis AG, Bemis DL, Stisser BC, Salomon L, Ghafar MA & Buttyan R 2003 Tumor cell hypoxia and the hypoxia-response signaling system as a target for prostate cancer therapy. Current Drug Targets 4 191-196.
6. Banham AH, Boddy J, Launchbury R, Han C, Turley H, Malone PR, Harris AL & Fox SB 2007 Expression of the forkhead transcription factor FOXP1 is associated both with hypoxia inducible factors (HIFs) and the androgen receptor in prostate cancer but is not directly regulated by androgens or hypoxia. Prostate 67 1091-1098.
7. Bauer B, Jenny M, Fresser F, Uberall F & Baier G 2003 AKT1/PKBalpha is recruited to lipid rafts and activated downstream of PKC isotypes in CD3-induced T cell signaling. FEBS Letters 541 155-162.
8. Boddy JL, Fox SB, Han C, Campo L, Turley H, Kanga S, Malone PR & Harris AL 2005 The androgen receptor is significantly associated with vascular endothelial growth factor and hypoxia sensing via hypoxia-inducible factors HIF-1a, HIF-2a, and the prolyl hydroxylases in human prostate cancer. Clinical Cancer Research 11 7658-7663.
9. Bonaccorsi L, Carloni V, Muratori M, Formigli L, Zecchi S, Forti G & Baldi E 2004a EGF receptor (EGFR) signaling promoting invasion is disrupted in androgen-sensitive prostate cancer cells by an interaction between EGFR and androgen receptor (AR). International Journal of Cancer 112 78-86.
10. Bonaccorsi L, Marchiani S, Muratori M, Forti G & Baldi E 2004b Gefitinib ('IRESSA', ZD1839) inhibits EGF-induced invasion in prostate cancer cells by suppressing PI3 K/AKT activation. Journal of Cancer Research and Clinical Oncology 130 604-614.
11. Bonaccorsi L, Nosi D, Muratori M, Formigli L, Forti G & Baldi E 2007 Altered endocytosis of epidermal growth factor receptor in androgen receptor positive prostate cancer cell lines. Journal of Molecular Endocrinology 38 51-66.
12. Bruckheimer EM & Kyprianou N 2001 Dihydrotestosterone enhances transforming growth factor-beta-induced apoptosis in hormone-sensitive prostate cancer cells. Endocrinology 142 2419-2426.
13. Bruckheimer EM & Kyprianou N 2002 BCL-2 antagonizes the combined apoptotic effect of transforming growth factor-beta and dihydrotestosterone in prostate cancer cells. Prostate 53 133-142.
14. Burfeind P, Chernicky CL, Rininsland F & Ilan J 1996 Antisense RNA to the type I insulin-like growth factor receptor suppresses tumor growth and prevents invasion by rat prostate cancer cells in vivo. PNAS 93 7263-7268.
15. Byrne RL, Leung H & Neal DE 1996 Peptide growth factors in the prostate as mediators of stromal epithelial interaction. British Journal of Urology 77 627-633.
16. Camps JL, Chang SM, Hsu TC, Freeman MR, Hong SJ, Zhau HE, von Eschenbach AC & Chung LW 1990 Fibroblast-mediated acceleration of human epithelial tumor growth in vivo. PNAS 87 75-79.
17. Cardillo MR, Petrangeli E, Perracchio L, Salvatori L, Ravenna L & Di Silverio F 2000 Transforming growth factor-beta expression in prostate neoplasia. Analytical and Quantitative Cytology and Histology 22 1-10.
18. Chipuk JE, Cornelius SC, Pultz NJ, Jorgensen JS, Bonham MJ, Kim SJ & Danielpour D 2002 The androgen receptor represses transforming growth factor-beta signaling through interaction with Smad3. Journal of Biological Chemistry 277 1240-1248.
19. Chung LW, Chang SM, Bell C, Zhau HE, Ro JY & von Eschenbach AC 1989 Co-inoculation of tumorigenic rat prostate mesenchymal cells with non-tumorigenic epithelial cells results in the development of carcinosarcoma in syngeneic and athymic animals. International Journal of Cancer 43 1179-1187.
20. Chung LW, Gleave ME, Hsieh JT, Hong SJ & Zhau HE 1991 Reciprocal mesenchymal-epithelial interaction affecting prostate tumour growth and hormonal responsiveness. Cancer Surveys 1191-121.
21. Coffey RJ Jr, Shipley GD & Moses HL 1986 Production of transforming growth factors by human colon cancer lines. Cancer Research 46 1164-1169.
22. Craft N, Shostak Y, Carey M & Sawyers CL 1999 A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinase. Nature Medicine 5 280-285.
23. Culig Z, Hobisch A, Cronauer MV, Radmayr C, Trapman J, Hittmair A, Bartsch G & Klocker H 1994 Androgen receptor activation in prostatic tumor cell lines by insulin-like growth factor-1, keratinocyte growth factor, and epidermal growth factor. Cancer Research 54 5474-5478.
24. Cunha GR & Donjacour AA 1989 Mesenchymal-epithelial interactions in the growth and development of the prostate. Cancer Treatment and Research 46 159-175.
25. Cunha GR, Hayward SW, Dahiya R & Foster BA 1996 Smooth muscle-epithelial interactions in normal and neoplastic prostatic development. Acta Anatomica 155 63-72.
26. Delongchamps NB, Peyromaure M & Dinh-Xuan AT 2006 Role of vascular endothelial growth factor in prostate cancer. Urology 68 244-248.
27. Derynck R & Zhang YE 2003 Smad-dependent and Smad-independent pathways in TGF-beta family signalling. Nature 425 577-584.
28. DiNitto JP, Cronin TC & Lambright DG 2003 Membrane recognition and targeting by lipid-binding domains. Science's STKE 2003 rel6.
29. Fan W, Yanase T, Morinaga H, Okabe T, Nomura M, Daitoku H, Fukamizu A, Kato S, Takayanagi R & Nawata H 2007 Insulin-like growth factor 1/ insulin signaling activates androgen signaling through direct interactions of Foxo1 with androgen receptor. Journal of Biological Chemistry 282 7329-7338.
30. Festuccia C, Muzi P, Millimaggi D, Biordi L, Gravina GL, Speca S, Angelucci A, Dolo V, Vicentini C & Bologna M 2005 Molecular aspects of gefitinib antiproliferative and pro-apoptotic effects in PTEN-positive and PTEN-negative prostate cancer cell lines. Endocrine-Related Cancer 12 983-998.
31. Fong GH, Rossant J, Gertsenstein M & Breitman ML 1995 Role of the Flt- 1 receptor tyrosine kinase in regulating the assembly of vascular endothelium. Nature 376 66-70.
32. Franck-Lissbrant I, Haggstrom S, Damber JE & Bergh A 1998 Testosterone stimulates angiogenesis and vascular regrowth in the ventral prostate in castrated adult rats. Endocrinology 139 451-456.
33. Freeman MR, Cinar B, Kim J, Mukhopadhyay NK, Di Vizio D, Adam RM & Solomon KR 2007 Transit of hormonal and EGF receptor-dependent signals through cholesterol-rich membranes. Steroids 72 210-217.
34. Gerdes MJ, Dang TD, Larsen M & Rowley DR 1998 Transforming growth factor-beta1 induces nuclear to cytoplasmic distribution of androgen receptor and inhibits androgen response in prostate smooth muscle cells. Endocrinology 139 3569-3577.
35. Gerdes MJ, Larsen M, Dang TD, Ressler SJ, Tuxhorn JA & Rowley DR 2004 Regulation of rat prostate stromal cell myodifferentiation by androgen and TGF-beta1. Prostate 58 299-307.
36. Gleave M, Hsieh JT, Gao CA, von Eschenbach AC & Chung LW 1991 Acceleration of human prostate cancer growth in vivo by factors produced by prostate and bone fibroblasts. Cancer Research 51 3753-3761.
37. Gonzalez-Herrera IG, Prado-Lourenco L, Pileur F, Conte C, Morin A, Cabon F, Prats H, Vaguer S, Bayard F, Audigier S et al. 2006 Testosterone regulates FGF-2 expression during testis maturation by an IRES-dependent translational mechanism. FASEB Journal 20 476-478.
38. Grossmann ME, Huang H & Tindall DJ 2001 Androgen receptor signaling in androgen-refractory prostate cancer. Journal of the National Cancer Institute 93 1687-1697.
39. Hayes SA, Zamegar M, Sharma M, Yang F, Peehl DM, ten Dijke P & Sun Z 2001 SMAD3 represses androgen receptor-mediated transcription. Cancer Research 61 2112-2118.
40. Hayward SW, Grossfeld GD, Tlsty TD & Cunha GR 1998 Genetic and epigenefic influences in prostatic carcinogenesis (review). International Journal of Oncology 13 35-47.
41. Heinlein CA & Chang C 2002 The roles of androgen receptors and androgen-binding proteins in nongenomic androgen actions. Molecular Endocrinology 16 2181-2187.
42. Heinlein CA & Chang C 2004 Androgen receptor in prostate cancer. Endocrine Reviews 25 276-308.
43. Henshall SM, Quinn DI, Lee CS, Head DR, Golovsky D, Brenner PC, Delprado W, Stricker PD, Grygiel JJ & Sutherland RL 2001 Altered expression of androgen receptor in the malignant epithelium and adjacent stroma is associated with early relapse in prostate cancer. Cancer Research 61 423-427.
44. Hobisch A, Eder TE, Putz T, Horninger W, Bartsch G, Klocker H & Culig Z 1998 Interleukin-6 regulates prostate-specific protein expression in prostate carcinoma cells by activation of the androgen receptor. Cancer Research 58 4640-4645.
45. Hsing AW 2001 Hormones and prostate cancer: what's next? Epidemiologic Reviews 23 42-58.
46. Imperato-McGinley J, Binienda Z, Arthur A, Mininberg DT, Vaughan ED Jr & Quimby FW 1985 The development of a male pseudohermaphroditic rat using an inhibitor of the enzyme 5 alpha-reductase. Endocrinology 116 807-812.
47. Joseph IB, Nelson JB, Denmeade SR & Isaacs JT 1997 Androgens regulate vascular endothelial growth factor content in normal and malignant prostatic tissue. Clinical Cancer Research 3 2507-2511.
48. Kalus W, Zweckstetter M, Renner C, Sanchez Y, Georgescu J, Grol M, Demuth D, Schumacher R, Dony C, Lang K et al. 1998 Structure of the IGF-binding domain of the insulin-like growth factor-binding protein-5 (IGFBP-5): implications for IGF and IGF-I receptor interactions. EMBO Journal 17 6558-6572.
49. Kang HY, Huang KE, Chang SY, Ma WL, Lin WJ & Chang C 2002 Differential modulation of androgen receptor-mediated transactivation by Smad3 and tumor suppressor Smad4. Journal of Biological Chemistry 277 43749-43756.
50. Kuhajda FP 2006 Fatty acid synthase and cancer: new application of an old pathway. Cancer Research 66 5977-5980.
51. Leotoing L, Manin M, Monte D, Baron S, Communal Y, Lours C, Veyssiere G, Morel L & Beaudoin C 2007 Crosstalk between androgen receptor and epidermal growth factor receptor-signalling pathways: a molecular switch for epithelial cell differentiation. Journal of Molecular Endocrinology 39 151-162.
52. Levine AC, Liu XH, Greenberg PD, Eliashvili M, Schiff JD, Aaronson SA, Holland JF & Kirschenbaum A 1998 Androgens induce the expression of vascular endothelial growth factor in human fetal prostatic fibroblasts. Endocrinology 139 4672-4678.
53. Lissbrant IF, Hammarsten P, Lissbrant E, Ferrara N, Rudolfsson SH & Bergh A 2004 Neutralizing VEGF bioactivity with a soluble chimeric VEGF-receptor protein flt(1-3)IgG inhibits testosterone-stimulated prostate growth in castrated mice. Prostate 58 57-65.
54. Liu Y, Majumder S, McCall W, Sartor CI, Mohler JL, Gregory CW, Earp HS & Whang YE 2005 Inhibition of HER-2/neu kinase impairs androgen receptor recruitment to the androgen responsive enhancer. Cancer Research 65 3404-3409.
55. Di Lorenzo G, Tortora G, D'Armiento FP, De Rosa G, Staibano S, Autorino R, D'Armiento M, De Laurentiis M, De Placido S, Catalano G et al. 2002 Expression of epidermal growth factor receptor correlates with disease relapse and progression to androgen-independence in human prostate cancer. Clinical Cancer Research 8 3438-3444.
56. Manin M, Veyssiere G, Cheyvialle D, Chevalier M, Lecher P & Jean C 1992 In vitro androgenic induction of a major protein in epithelial cell subcultures from mouse vas deferens. Endocrinology 131 2378-2386.
57. Manin M, Martinez A, Van Der Schueren B, Reynaert I & Jean C 2000 Acquisition of androgen-mediated expression of mouse vas deferens protein (MVDP) gene in cultured epithelial cells and in vas deferens during postnatal development. Journal of Andrology 21 641-650.
58. Manin M, Baron S, Goossens K, Beaudoin C, Jean C, Veyssiere G, Verhoeven G & Morel L 2002 Androgen receptor expression is regulated by the phosphoinositide 3-kinase/Akt pathway in normal and tumoral epithelial cells. Biochemical Journal 366 729-736.
59. De Marzo AM, Nelson WG, Meeker AK & Coffey DS 1998 Stem cell features of benign and malignant prostate epithelial cells. Journal of Urology 160 2381-2392.
60. Mellinghoff IK, Vivanco I, Kwon A, Tran C, Wongvipat J & Sawyers CL 2004 HER2/neu kinase-dependent modulation of androgen receptor function through effects on DNA binding and stability. Cancer Cell 6 517-527.
61. Memarzadeh S, Xin L, Mulholland DJ, Mansukhani A, Wu H, Teitell MA & Witte ON 2007 Enhanced paracrine FGF10 expression promotes formation of multifocal prostate adenocarcinoma and an increase in epithelial androgen receptor. Cancer Cell 12 572-585.
62. Myers RB, Oelschlager D, Marine U, Coan PN, Weiss H & Grizzle WE 1999 Androgenic regulation of growth factor and growth factor receptor expression in the CWR22 model of prostatic adenocarcinoma. International Journal of Cancer 82 424-429.
63. Nakano K, Fukabori Y, Itoh N, Lu W, Kan M, McKeehan WL & Yamanaka H 1999 Androgen-stimulated human prostate epithelial growth mediated by stromal-derived fibroblast growth factor-10. Endocrine Journal 46 405-413.
64. Nickerson T, Chang F, Lorimer D, Smeekens SP, Sawyers CL & Pollak M 2001 In vivo progression of LAPC-9 and LNCaP prostate cancer models to androgen independence is associated with increased expression of insulin-like growth factor I (IGF-I) and IGF-I receptor (IGF-IR). Cancer Research 61 6276-6280.
65. Niu Y, Xu Y, Zhang J, Bai J, Yang H & Ma T 2001 Proliferation and differentiation of prostatic stromal cells. BJU International 87 386-393.
66. Ohlson N, Bergh A, Stattin P & Wikstrom P 2007 Castration-induced epithelial cell death in human prostate tissue is related to locally reduced IGF-1 levels. Prostate 67 32-40.
67. Orio F Jr, Terouanne B, Georget V, Lumbroso S, Avances C, Siatka C & Sultan C 2002 Potential action of IGF-1 and EGF on androgen receptor nuclear transfer and transactivation in normal and cancer human prostate cell lines. Molecular and Cellular Endocrinology 198 105-114.
68. Ornitz DM & Itoh N 2001 Fibroblast growth factors. Genome Biology 2 REVIEWS3005.
69. Peterziel H, Mink S, Schonert A, Becker M, Klocker H & Cato AC 1999 Rapid signalling by androgen receptor in prostate cancer cells. Oncogene 18 6322-6329.
70. Pollak M, Beamer W & Zhang JC 1998 Insulin-like growth factors and prostate cancer. Cancer and Metastasis Reviews 17 383-390.
71. Rabinovitz I, Gipson IK & Mercurio AM 2001 Traction forces mediated by alpha6beta4 integrin: implications for basement membrane organization and tumor invasion. Molecular Biology of the Cell 12 4030-4043.
72. Rinaldo F, Li J, Wang E, Muders M & Datta K 2007 Ra1A regulates vascular endothelial growth factor-C (VEGF-C) synthesis in prostate cancer cells during androgen ablation. Oncogene 26 1731-1738.
73. Roberts JT & Essenhigh DM 1986 Adenocarcinoma of prostate in 40-year-old body-builder. Lancet 2 742.
74. Roberts AB, Spom MB, Assoian RK, Smith JM, Roche NS, Wakefield LM, Heine UI, Liotta LA, Falanga V, Kehrl JH et al. 1986 Transforming growth factor type beta: rapid induction of fibrosis and angiogenesis in vivo and stimulation of collagen formation in vitro. PNAS 83 4167-4171.
75. Rosini P, Bonaccorsi L, Baldi E, Chiasserini C, Forti G, De Chiara G, Lucibello M, Mongiat M, Iozzo RV, Garaci E et al. 2002 Androgen receptor expression induces FGF2, FGF-binding protein production, and FGF2 release in prostate carcinoma cells: role of FGF2 in growth, survival, and androgen receptor down-modulation. Prostate 53 310-321.
76. Russell PJ, Bennett S & Stricker P 1998 Growth factor involvement in progression of prostate cancer. Clinical Chemistry 44 705-723.
77. Salm SN, Koikawa Y, Ogilvie V, Tsujimura A, Coetzee S, Moscatelli D, Moore E, Lepor H, Shapiro E, Sun TT et al. 2000 Generation of active TGF-beta by prostatic cell cocultures using novel basal and luminal prostatic epithelial cell lines. Journal of Cellular Physiology 184 70-79.
78. Sar M, Lubahn DB, French FS & Wilson EM 1990 Immunohistochemical localization of the androgen receptor in rat and human tissues. Endocrinology 127 3180-3186.
79. Saric T & Shain SA 1998 Androgen regulation of prostate cancer cell FGF-1, FGF-2, and FGF-8: preferential down-regulation of FGF-2 transcripts. Growth Factors 16 69-87.
80. Siiteri PK & Wilson JD 1974 Testosterone formation and metabolism during male sexual differentiation in the human embryo. Journal of Clinical Endocrinology and Metabolism 38 113-125.
81. Simons K & Toomre D 2000 Lipid rafts and signal transduction. Nature Reviews. Molecular Cell Biology 1 31-39.
82. Sporn MB & Roberts AB 1992 Transforming growth factor-beta: recent progress and new challenges. Journal of Cell Biology 119 1017-1021.
83. Torring N, Dagnaes-Hansen F, Sorensen BS, Nexo E & Hynes NE 2003 ErbB1 and prostate cancer: ErbB1 activity is essential for androgen-induced proliferation and protection from the apoptotic effects of LY294002. Prostate 56 142-149.
84. Ueda T, Mawji NR, Bruchovsky N & Sadar MD 2002 Ligand-independent activation of the androgen receptor by interleukin-6 and the role of steroid receptor coactivator-1 in prostate cancer cells. Journal of Biological Chemistry 277 38087-38094.
85. Wang H, Song K, Sponseller TL & Danielpour D 2005 Novel function of androgen receptor-associated protein 55/Hic-5 as a negative regulator of Smad3 signaling. Journal of Biological Chemistry 280 5154-5162.
86. Wang X, Yin L, Rao P, Stein R, Harsch KM, Lee Z & Heston WD 2007 Targeted treatment of prostate cancer. Journal of Cellular Biochemistry 102 571-579.
87. Wells A, Kassis J, Solava J, Turner T & Lauffenburger DA 2002 Growth factor-induced cell motility in tumor invasion. Acta Oncologica 41 124-130.
88. Wolk A, Mantzoros CS, Andersson SO, Bergstrom R, Signorello LB, Lagiou P, Adami HO & Trichopoulos D 1998 Insulin-like growth factor 1 and prostate cancer risk: a population-based, case-control study. Journal of the National Cancer Institute 90 911-915.
89. Wu Y, Zhao W, Zhao J, Pan J, Wu Q, Zhang Y, Bauman WA & Cardozo CP 2007 Identification of androgen response elements in the insulin-like growth factor I upstream promoter. Endocrinology 148 2984-2993.
90. Xue C, Wyckoff J, Liang F, Sidani M, Violini S, Tsai KL, Zhang ZY, Sahai E, Condeelis J & Segall JE 2006 Epidermal growth factor receptor overexpression results in increased tumor cell motility in vivo coordinately with enhanced intravasation and metastasis. Cancer Research 66 192-197.
91. Yeh S, Lin HK, Kang HY, Thin TH, Lin MF & Chang C 1999 From HER2/Neu signal cascade to androgen receptor and its coactivators: a novel pathway by induction of androgen target genes through MAP kinase in prostate cancer cells. PNAS 96 5458-5463.
92. Yoon G, Kim JY, Choi YK, Won YS & Lim IK 2006 Direct activation of TGF-betal transcription by androgen and androgen receptor complex in Huh7 human hepatoma cells and its tumor in nude mice. Journal of Cellular Biochemistry 97 393-411.
93. Yoshizawa A & Ogikubo S 2006 IGF binding protein-5 synthesis is regulated by testosterone through transcriptional mechanisms in androgen responsive cells. Endocrine Journal 53 811-818.
94. Zavadil J & Bottinger EP 2005 TGF-beta and epithelial-to-mesenchymal transitions. Oncogene 24 5764-5774.
95. Zhu B & Kyprianou N 2005 Transforming growth factor beta and prostate cancer. Cancer Treatment and Research 126 157-173.
96. Zhu B, Fukada K, Zhu H & Kyprianou N 2006 Prohibitin and cofilin are intracellular effectors of transforming growth factor beta signaling in human prostate cancer cells. Cancer Research 66 8640-8647.
97. Zhu ML, Partin JV, Bruckheimer EM, Strup SE & Kyprianou N 2008 TGF-beta signaling and androgen receptor status determine apoptotic cross-talk in human prostate cancer cells. Prostate 68 287-295.
98. Zhuang L, Kim J, Adam RM, Solomon KR & Freeman MR 2005 Cholesterol targeting alters lipid raft composition and cell survival in prostate cancer cells and xenografts. Journal of Clinical Investigation 115 959-968.